摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-硫杂双环[3.2.1]辛烷 | 279-91-4

中文名称
6-硫杂双环[3.2.1]辛烷
中文别名
——
英文名称
6-Thiabicyclo<3.2.1>octan
英文别名
6-Thiabicyclo[3.2.1]octane
6-硫杂双环[3.2.1]辛烷化学式
CAS
279-91-4
化学式
C7H12S
mdl
——
分子量
128.238
InChiKey
FMOJLLCYRLEUSL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    172.5-174.0 °C(Solv: acetic acid (64-19-7))
  • 沸点:
    197 °C(Press: 769 Torr)
  • 密度:
    1.047±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.2
  • 重原子数:
    8
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    25.3
  • 氢给体数:
    0
  • 氢受体数:
    1

安全信息

  • 海关编码:
    2934999090

SDS

SDS:460c2e87eea4abc162b2dd17af2ef511
查看

反应信息

  • 作为产物:
    参考文献:
    名称:
    Preparation and Physical Properties of Sulfur Compounds Related to Petroleum. VII. 2-, 6- and 8-Thiabicyclo[3.2.1]octane and 2-Thiabicyclo[2.2.2]octane
    摘要:
    DOI:
    10.1021/jo01363a015
点击查看最新优质反应信息

文献信息

  • PYRAZOLE COMPOUND
    申请人:Sasaki Izumi
    公开号:US20130116296A1
    公开(公告)日:2013-05-09
    The present invention relates to a novel serotonin reuptake inhibitor which also exhibits 5-HT 2C antagonistic action (antidepressive and anxiolytic effects), in particular, 5-HT 2C inverse agonistic action comprising Compound (1): or a pharmaceutically acceptable salt thereof wherein R 1 , R 2 , R 3 and R 4 are independently hydrogen or C 1-6 alkyl etc.; R 5 is C 4-7 alkyl or —(CR 8 R 9 ) r -E; R 6 , R 7 , R 8 and R 9 are independently hydrogen, fluorine or C 1-6 alkyl; A is C 6-10 aryl or heteroaryl etc.; r is 1, 2, 3 or 4; E is C 3-8 cycloalkyl or C 6-10 aryl etc.; L is oxygen, sulfur or —NR 10 —; n is 1, 2 or 3; R 10 is hydrogen or C 1-6 alkyl etc.; and X is hydrogen or halogen etc.
    本发明涉及一种新型的血清素再摄取抑制剂,同时还表现出5-HT2C拮抗作用(抗抑郁和抗焦虑效果),特别是包括化合物(1)的5-HT2C逆作动作:或其药学上可接受的盐,其中R1、R2、R3和R4独立地为氢或C1-6烷基等;R5为C4-7烷基或—(CR8R9)r-E;R6、R7、R8和R9独立地为氢、或C1-6烷基;A为C6-10芳基或杂环芳基等;r为1、2、3或4;E为C3-8环烷基或C6-10芳基等;L为氧、或—NR10—;n为1、2或3;R10为氢或C1-6烷基等;X为氢或卤素等。
  • [EN] MONOBACTAMS AND METHODS OF THEIR SYNTHESIS AND USE<br/>[FR] MONOBACTAMES ET PROCÉDÉS DE SYNTHÈSE ET D'UTILISATION DE CES DERNIERS
    申请人:HARVARD COLLEGE
    公开号:WO2015103583A1
    公开(公告)日:2015-07-09
    Described herein are monobactam antibiotics of Formula (I), (Ι'), (II), and (II'), along with methods and intermediates for preparing these compounds. Pharmaceutical compositions and methods of treating infectious diseases using the monobactams are also provided.
    本文描述了单环内酰胺抗生素的化学式(I)、(Ι')、(II)和(II'),以及制备这些化合物的方法和中间体。还提供了使用单环内酰胺治疗传染病的药物组合物和方法。
  • THERAPEUTIC AGENT FOR NON-MOTOR SYMPTOMS ASSOCIATED WITH PARKINSON'S DISEASE
    申请人:Sumitomo Dainippon Pharma Co., Ltd.
    公开号:EP3569233A1
    公开(公告)日:2019-11-20
    The purpose of the present invention is to provide: a therapeutic agent or a recurrence preventive agent for serotonergic system- or dopaminergic system-related diseases, in particular, mental dysfunction symptoms and other non-motor symptoms of Parkinson's disease; and a method for treating the aforesaid symptoms or preventing the recurrence of the same. A compound represented by formula (1) [wherein each symbol is as defined in the description] or a pharmaceutically acceptable salt thereof can exhibit an effect of treating serotonergic system- or dopaminergic system-related diseases, in particular, mental dysfunction symptoms and other non-motor symptoms of Parkinson's disease and/or an effect of preventing the recurrence of the same.
    本发明的目的是提供:一种治疗5-羟色胺能系统或多巴胺能系统相关疾病,特别是帕森病的精神功能障碍症状和其他非运动症状的治疗剂或复发预防剂;以及一种治疗上述症状或预防上述症状复发的方法。由式(1)代表的化合物[其中各符号如描述中所定义]或其药学上可接受的盐可以显示出治疗血清素能系统或多巴胺能系统相关疾病的效果,特别是精神功能障碍症状和帕森病的其他非运动症状,和/或防止其复发的效果。
  • Pyrazole compound
    申请人:Sumitomo Dainippon Pharma Co., Ltd.
    公开号:US10723703B2
    公开(公告)日:2020-07-28
    The present invention relates to a novel serotonin reuptake inhibitor which also exhibits 5-HT2C antagonistic action (antidepressive and anxiolytic effects), in particular, 5-HT2C inverse agonistic action comprising Compound (1): or a pharmaceutically acceptable salt thereof wherein R1, R2, R3 and R4 are independently hydrogen or C1-6 alkyl etc.; R5 is C4-7 alkyl or —(CR8R9)r-E; R6, R7, R8 and R9 are independently hydrogen, fluorine or C1-6 alkyl; A is C6-10 aryl or heteroaryl etc.; r is 1, 2, 3 or 4; E is C3-8 cycloalkyl or C6-10 aryl etc.; L is oxygen, sulfur or —NR10—; n is 1, 2 or 3; R10 is hydrogen or C1-6 alkyl etc.; and X is hydrogen or halogen etc.
    本发明涉及一种新型血清素再摄取抑制剂,它还具有 5-HT2C 拮抗作用(抗抑郁和抗焦虑作用),特别是 5-HT2C 反激动作用,由化合物(1)组成: 或其药学上可接受的盐 其中 R1、R2、R3 和 R4 独立地为氢或 C1-6 烷基等;R5 为 C4-7 烷基或-(CR8R9)r-E;R6、R7、R8 和 R9 独立地为氢、或 C1-6 烷基;A 为 C6-10 芳基或杂芳基等。r为 1、2、3 或 4;E 为 C3-8 环烷基或 C6-10 芳基等;L 为氧、或-NR10-;n 为 1、2 或 3;R10 为氢或 C1-6 烷基等;X 为氢或卤素等。
  • FRESHENING COMPOSITIONS RESISTING SCENT HABITUATION
    申请人:The Procter & Gamble Company
    公开号:EP3268458A1
    公开(公告)日:2018-01-17
查看更多

同类化合物

硫杂环庚烷-2-酮 硫杂环庚烷 环己硫醚 桉叶硫醚 四氢-6-硫代-1,4-乙桥-1H,3H-噻吩并(3,4-c)噻吩-3-酮 二氢-7-丁基-1,4-乙桥-1H,3H-噻吩并(3,4-c)噻吩-3,6(4H)-二酮 二氢-1,4-二甲基-1,4-乙桥-1H,3H-噻吩并(3,4-c)噻吩-3,6(4H)-二酮 二氢-1,4-乙基桥-1H,3H-噻吩并(3,4-c)噻吩-3,6(4H)-二酮 β.-D-半乳吡喃糖,1,6-二脱氧-1,6-环硫- 6-硫杂双环[3.2.1]辛烷 6-甲基-7-硫杂二环[4.1.0]庚烷 5-氧代噻吩-3-羧酸甲酯 5-氧代-4-噻吩甲酸乙酯 4,7,7-三甲基-6-硫代二环[3.2.1]辛烷 3-硫杂二环[3.2.1]辛烷-2-酮,1,8,8-三甲基-,(1R)- 3-甲基噻吩1,1-二氧化物 3-(4-甲基苯基)噻吩1,1-二氧化物 2-羟基噻烷 1-癸基2-[[1-(2-氯-5-磺基苯基)-4,5-二氢-3-甲基-5-羰基-1H-吡唑-4-基]偶氮]苯酸酯 1,6:4,5-二去氢-2,3-二脱氧-1-硫代己糖醇 (1S,4S,5S)-4,7,7-三甲基-6-硫代二环[3.2.4]辛烷 (-)-2,10-(3,3二氯樟脑)磺内酰胺 hexahydro-2,5-methano-thiopyrano[3,2-b]furan 4,4-dioxide (3aR,6R,6aR)-2,2-Dimethyl-4-(2-methyl-[1,3]dithian-2-yl)-6-(tetrahydro-pyran-2-yloxymethyl)-tetrahydro-furo[3,4-d][1,3]dioxol-4-ol trans-4,5-Dihydroxythiocane 3,4-dichloro-3-methyl-tetrahydro-thiophene 1,3-di-O-acetyl-2,5-anhydro-4-O-methyl-6-thio-α-D-glucoseptanose DL-(1,5/4)-4,7-O-benzylidene-5-C-hydroxymethyl-1,4-cyclohexanediol (1R,5S)-9-Thia-tricyclo[3.3.1.02,4]nonane 9,9-dioxide (1R,2R,5R,6S,9S,10S)-12-thiatetracyclo[8.3.0.02,5.06,9]tridecane Perhydro-bis-pyrano<2.3-b:3'.2'-e>-1,4-oxathian torilensulfat 2-acetoxy-1,5-dithiacyclooctane 1,2,4,6-Tetrakis-trifluoromethyl-3,5,7-trithia-tricyclo[4.1.0.02,4]heptane (2R,4R,6R)-4-Chloro-6-(1,2-dichloro-ethyl)-4-methyl-[1,2]oxathiane 2-oxide 2-[1,3,5]Trithian-2-yl-cyclohexanol trans-(RuCl2(S(CH2)3CH2)4) 4,6,7,7-tetramethyl-2-thia-bicyclo(2.2.2)oct-5-ene 2,2-dioxide (1R,5R)-9-Oxa-3,7-dithia-tricyclo[3.3.1.02,4]nonane 3,3,7,7-tetraoxide Dodecahydro-thianthren-tetroxyd {Rh2Cl2(μ-CO)(bis(ethylthio)methane)2} 2-(8β-hydroxy-1β-methyl-7β,2α,6α-tricyclo<5.4.0.02,6>undecyl)1,3-dithiane 17β-Hydroxymethyl-estra-4,8(14)-dien-3,3-ethylendithioketal (9'S,10'S,13'R,17'S)-17'-(4,4-dimethyl-3-methylenepentyl)-9',10',13'-trimethyl-1',2',6',7',9',10',11',12',13',15',16',17'-dodecahydrospiro[cyclopentane-1,3'-cyclopenta[a]phenanthrene] 1,2,3,4,5,6,7,8,8a,10a-Decahydro-9,10-dithiaphenanthren Acetic acid (3R,4S,5S,6R)-5-acetoxy-3,6-dimethoxy-thiepan-4-yl ester 3,4-Di-sec.-butoxysulfolan 1,8,15,22,29,36-hexathia-cyclodotetracontane (3aS,7aR)-3a,7a-Dimethyl-1,3,3a,4,7,7a-hexahydro-benzo[c]thiophene